Oncopeptides Presents First Interim Data From the Ongoing Combination Trial ANCHOR With Melflufen at the 60th American Society of Hematology Meeting

STOCKHOLM, Dec. 2, 2018 /PRNewswire/ -- Overall conclusions The combinations of melflufen and dexamethasone (dex) with either bortezomib or daratumumab in relapsed-refractory multiple myeloma (RRMM) patients are well tolerated No dose limiting toxicity has been observed at the melflufen...

from PR Newswire: https://ift.tt/2AJkhCs